RASSF1 and non-small cell lung carcinoma: Regarding NSCLC, that hypoxia could disrupt the RASSF1A/Hippo signaling pathway, is of particular interest since Hippo pathway is already known to be altered following the loss of expression of RASSF1A in 25% of patient with NSCLC [13], leading to aberrant activation of both the Hippo kinase, NDR2 and the Hippo effector, YAP [14] and supporting the subsequent initiation and dissemination of NSCLC [14, 15].